Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/26/2005US20050112093 Combination therapy for HCV infection
05/26/2005US20050112088 Water solubility; polymer joining active materials
05/26/2005US20050112087 Pharmaceutical formulations for sustained drug delivery
05/26/2005US20050112082 Administering an oxydiamide compound ; humectant and skin barrier properties
05/26/2005US20050112078 Skin care; cosmetics
05/26/2005US20050112071 Hypoestoxides, derivatives, agonists and crude extracts thereof for use in cosmetic compositions
05/26/2005US20050112069 Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist
05/26/2005US20050112067 Analgesically effective amount of opioid analgesic is combined with polymer to form a matrix
05/26/2005US20050112066 Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity
05/26/2005US20050112062 Anti-idiotypic vascular endothelial growth factor antibodies and their use as medicaments
05/26/2005US20050112059 Enhancement of radiotherapy by an exogenous cardiac glycoside
05/26/2005US20050112058 Auger effect-based cancer therapy method
05/26/2005US20050112021 Reduction of Contaminants In Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light
05/26/2005US20050109981 Neutralize biological pathogens; sterilization of medical equipment; food processing equipment; mixture of bleaching activator, base and water
05/26/2005CA2547474A1 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter
05/26/2005CA2546115A1 Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
05/26/2005CA2546079A1 Lipometabolism improver containing pine bark extract
05/26/2005CA2545876A1 Crystalline topotecan hydrochloride product and process for making the same
05/26/2005CA2545781A1 Bicyclic pyrazolone cytokine inhibitors
05/26/2005CA2545771A1 Migraine treatments including isovaleramide compounds and serotonin agonists
05/26/2005CA2545752A1 Treatment and prevention of liver disease associated with parenteral nutrition (pn)
05/26/2005CA2545731A1 Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders
05/26/2005CA2545677A1 Method for drug loading in liposomes
05/26/2005CA2545617A1 Novel oxy-nitriles
05/26/2005CA2545606A1 Carbohydrate and electrolyte replacement composition
05/26/2005CA2545558A1 Pyridopyrimidinones
05/26/2005CA2545443A1 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
05/26/2005CA2545435A1 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005CA2545433A1 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005CA2545423A1 Combinations for the treatment of proliferative diseases
05/26/2005CA2545384A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
05/26/2005CA2545373A1 Novel 1,3-disubstituted azetidine derivatives for use as 5ht2a receptor ligands
05/26/2005CA2545364A1 Methods of modulating angiogenesis and cancer cell proliferation
05/26/2005CA2545350A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors
05/26/2005CA2545340A1 Fused heterocyclic compounds
05/26/2005CA2545276A1 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
05/26/2005CA2545259A1 Heteroaryl-hydrazone compounds
05/26/2005CA2545258A1 Pyridine compounds
05/26/2005CA2545254A1 Substituted triazoles as sodium channel blockers
05/26/2005CA2545204A1 Compositions of a cholesterol biosynthesis inhibitor and a soluble fiber for the treatment of conditions associated with elevated cholesterol levels
05/26/2005CA2545190A1 Agent for preventing and treating language disorders
05/26/2005CA2545182A1 Improved methods and compositions for rna interference
05/26/2005CA2545133A1 Use of glucosidase inhibitors for therapy of mucovisidosis
05/26/2005CA2545117A1 Virucidal activities of a combination of cetylpyridinium chloride and citric acid
05/26/2005CA2545062A1 Selective inhibitors of nuclear factor-kb activation and uses thereof
05/26/2005CA2545060A1 Methods of use of thrombin receptor antagonists
05/26/2005CA2545058A1 4-biarylyl-1-phenylazetidin-2-ones
05/26/2005CA2545055A1 Macrocyclic kinase inhibitors
05/26/2005CA2545020A1 Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
05/26/2005CA2544981A1 4-phenyl piperidine sulfonyl glycine transporter inhibitors
05/26/2005CA2544923A1 Method and antisense compound for potentiating anti-cancer agents
05/26/2005CA2544747A1 At1-receptor antagonists for treating nephrotic syndrome
05/26/2005CA2544693A1 Methods and compositions for selectin inhibition
05/26/2005CA2544684A1 Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
05/26/2005CA2544621A1 Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance
05/26/2005CA2544603A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2544602A1 Therapeutic compounds and uses thereof
05/26/2005CA2544599A1 Methods of treating eczema
05/26/2005CA2544591A1 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2544589A1 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2544550A1 Use of thienopyrimidines
05/26/2005CA2544503A1 Pharmaceutical composition consisting of a beta-3 adrenoceptor agonist and an alpha agonist
05/26/2005CA2544500A1 Use of haloarylpyrazole compounds in the control of parasite infestation on animals
05/26/2005CA2544492A1 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
05/26/2005CA2544421A1 Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
05/26/2005CA2544413A1 Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative
05/26/2005CA2544349A1 Rna amidates and thioamidates for rnai
05/26/2005CA2544309A1 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
05/26/2005CA2544247A1 Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
05/26/2005CA2544245A1 Use of selective opiate receptor modulators in the treatment of neuropathy
05/26/2005CA2544191A1 Substituted naphthyridinone derivatives
05/26/2005CA2544186A1 Inhibition of fgfr3 and treatment of multiple myeloma with benzimidazole quinolinones
05/26/2005CA2544048A1 Pharmaceutical composition for treating stress incontinence and/or mixed incontinence
05/26/2005CA2543926A1 Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
05/26/2005CA2543913A1 Benzylether amine compounds useful as ccr-5 antagonists
05/26/2005CA2543811A1 Compositions and methods for diagnosing and treating mental disorders
05/26/2005CA2543806A1 Combined cosmetic or therapeutic preparation
05/26/2005CA2543765A1 Methods and compositions for selectin inhibition
05/26/2005CA2543629A1 2-phenyl-benzofuran derivatives, method for the production thereof and their use
05/26/2005CA2543627A1 Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
05/26/2005CA2543596A1 Hdl-boosting combination therapy complexes
05/26/2005CA2543582A1 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
05/26/2005CA2543294A1 Methods and compositions for identifying therapeutic compounds
05/26/2005CA2543163A1 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
05/26/2005CA2542547A1 Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
05/26/2005CA2541949A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
05/26/2005CA2540725A1 Stimulation of hair growth by ginkgo biloba flavonoids
05/26/2005CA2540383A1 Method for preparing submicron particles of paclitaxel
05/26/2005CA2536041A1 Medical implants and fibrosis-inducing agents
05/26/2005CA2534342A1 Amino acid prodrugs
05/26/2005CA2527904A1 Lactoferrin as an adjuvant in cancer vaccines
05/25/2005EP1533619A2 Specific markers for metabolic syndrome
05/25/2005EP1533382A1 Beta glucan-containing fat and oil compositions and novel microorganism capable of producing beta-glucan
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
05/25/2005EP1533313A1 Novel derivative of flavone c-glycoside and composition containing the same
05/25/2005EP1533312A1 Hetero-bicyclic compounds
05/25/2005EP1533305A1 A process for the preparation of valsartan and intermediates thereof
05/25/2005EP1533304A1 Amide derivative
05/25/2005EP1533298A1 3-aminopyrrolidone derivatives
05/25/2005EP1533295A1 Cyclopentyl Derivatives
1 ... 4678 4679 4680 4681 4682 4683 4684 4685 4686 4687 4688 4689 4690 4691 4692 4693 4694 4695 4696 4697 4698 ... 7860